Thyer R, Shroff R, Klein DR, d'Oelsnitz S, Cotham VC, Byrom M, Brodbelt J, Ellington A (2018) Custom selenoprotein production enabled by laboratory evolution of recoded bacterial strains. Nature Biotechnology, EPub ahead of print.
https://www.nature.com/articles/nbt.4154A year ago, a group of scientists convened in New York City to discuss an audacious plan: construct an entire human genome from scratch.
To uncover the mission of GRO Biosciences Inc., one has to look no further than its name. The acronym stands for “genomically recoded organisms”
Harvard geneticist and serial biotech entrepreneur George Church has co-founded a new startup that aims to develop “designer proteins” targeting a range of disorders.
GRO Biosciences Inc. wants to make a giant sector in the pharmaceutical industry even larger. The spinout from the lab of Harvard Medical School geneticist George Church aims to make protein drugs more versatile and effective
Biology is computation. It operates on the digital alphabet of biochemistry, which is quite a bit more complicated than binary, hex, or even Haskell.
BOSTON, Sept. 28, 2017 – GRO Biosciences Inc. today announced that the company has secured $2.1 million in a seed funding round co-led by Digitalis Ventures and Eric Schmidt’s Innovation Endeavors.
Ostrov N, Landon M, Guell M, Kuznetsov G, Teramoto J, Cervantes N, Zhou M, Singh K, Napolitano MG, Moosburner M, Shrock E, Pruitt BW, Conway N, Goodman DB, Gardner C, Tyree G, Gonzales A, Wanner BL, Norville J, Lajoie MJ, Church GM (2016) Design, Synthesis and Testing Towards a 57-Codon Genome. Science 353(6301):819-22. PMID: 27540174
https://pubmed.ncbi.nlm.nih.gov/27540174/